Dendritic Cell / Multiple Myeloma Fusion Vaccine
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 25 patients (estimated)
- Sponsors
- Beth Israel Deaconess Medical Center
- Collaborators
- Pfizer
- Tags
- Vaccine
- Trial Type
- Treatment
- Last Update
- 4 months ago
- SparkCures ID
- 2056
- NCT Identifier
- NCT06799026
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.